These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 15654855

  • 1. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
    Lane EL, Cheetham SC, Jenner P.
    Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
    [Abstract] [Full Text] [Related]

  • 2. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL, Cheetham SC, Jenner P.
    Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
    [Abstract] [Full Text] [Related]

  • 3. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 4. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C, Jiménez A, Tolosa E, Bonastre M, Bové J.
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [Abstract] [Full Text] [Related]

  • 5. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [Abstract] [Full Text] [Related]

  • 6. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 7. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
    Lane EL, Cheetham S, Jenner P.
    J Neural Transm (Vienna); 2008 Jun; 115(3):423-9. PubMed ID: 18250952
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.
    Mov Disord; 2002 Sep 01; 17(5):887-901. PubMed ID: 12360537
    [Abstract] [Full Text] [Related]

  • 12. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Rose S, Ramsay Croft N, Jenner P.
    Brain Res; 2007 Feb 16; 1133(1):110-4. PubMed ID: 17196564
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats.
    Papathanou M, Rose S, McCreary A, Jenner P.
    Eur J Neurosci; 2011 Jun 16; 33(12):2247-54. PubMed ID: 21615558
    [Abstract] [Full Text] [Related]

  • 15. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
    Lundblad M, Picconi B, Lindgren H, Cenci MA.
    Neurobiol Dis; 2004 Jun 16; 16(1):110-23. PubMed ID: 15207268
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 17. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
    Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA.
    Behav Brain Res; 2007 Feb 12; 177(1):150-9. PubMed ID: 17157933
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.